Recent advances in peptide-based subunit nanovaccines

Nanomedicine

Volumn 9, Issue 17, 2014, Pages 2657-2669

  Skwarczynski, Mariusz ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

adjuvant; dendrimers; lipids; macromolecules; nanoparticles; nanotechnology; peptide vaccine; polymer; self assembly; vaccine delivery

Indexed keywords

BOMBESIN; CHITOSAN; LIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN 1; NANOMATERIAL; NANOPARTICLE; NANOTUBE; NANOVACCINE; PEPTIDE; PEPTIDE VACCINE; PHOSPHORYL LIPID A; POLYMER; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COVALENT BOND; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; HUMORAL IMMUNITY; HYDROPHOBICITY; MATERIALS; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PINOCYTOSIS; REVIEW; TUMOR ESCAPE;

EID: 84919791494     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.187     Document Type: Review

References (83)

1. Skwarczynski M, Toth I. Peptide-based subunit nanovaccines. Curr. Drug Delivery 8(3), 282-289 (2011).
2. Bachmann MF, Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787-796 (2010).
3. Oyewumi MO, Kumar A, Cui ZR. Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9(9), 1095-1107 (2010).
4. Fujita Y, Taguchi H. Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles. Chem. Cent. J. 5 (2011).
5. Zaman M, Good MF, Toth I. Nanovaccines and their mode of action. Methods 60(3), 226-231 (2013).
6. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv. Drug Delivery Rev. 62, 394-407 (2010).
7. Nandedkar TD. Nanovaccines: Recent developments in vaccination. J. Biosci. 34(6), 995-1003 (2009).
8. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Delivery Rev. 60(8), 915-928 (2008).
9. Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: Does size matter? Methods 40(1), 1-9 (2006).
10. Hussein WM, Liu T-Y, Skwarczynski M, Toth I. Toll-like receptor agonists: A patent review (2011-2013). Expert Opin. Ther. Pat. 24(4), 453-470 (2014).
11. Keler T, Ramakrishna V, Fanger MW. Mannose receptor-Targeted vaccines. Expert Opin. Biol. Ther. 4(12), 1953-1962 (2004).
12. Azmi F, Ahmad Fuaad AaH, Skwarczynski M, Toth I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum. Vaccin. Immunother. 10(3), 778-796 (2014).
13. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12(8), 557-569 (2012).
14. Liu TY, Hussein WM, Toth I, Skwarczynski M. Advances in peptide-based human papillomavirus therapeutic vaccines. Curr. Top. Med. Chem. 12, 1581-1592 (2012).
15. Purcell AW, Mccluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6(5), 404-414 (2007).
16. Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW. Epitope discovery and their use in peptide based vaccines. Curr. Pharm. Des. 16(28), 3149-3157 (2010).
17. Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 104(1), 15-21 (2013).
18. Doll TaPF, Raman S, Dey R, Burkhard P. Nanoscale assemblies and their biomedical applications. J. Royal Soc. Interface 10(80), 20120740 (2013).
19. Sahdev P, Ochyl LJ, Moon JJ. Biomaterials for nanoparticle vaccine delivery systems. Pharm. Res. 31(10), 2563-2582 (2014).
20. McCoy M. Long-Term partners. Chem. Eng. News 91(9), 18-19 (2013).
21. Akagi T, Baba M, Akashi M. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: Regulation of immune responses by nanoparticle-based vaccine. In: Polymers in Nanomedicine. Kunugi S, Yamaoka T (Eds). Springer-Verlag Berlin, Berlin, Germany, 31-64 (2012).
22. Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173(5), 3148-3154 (2004).
23. Mottram PL, Leong D, Crimeen-Irwin B et al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: Formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 4(1), 73-84 (2007).
24. Reddy ST, Van Der Vlies AJ, Simeoni E et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25(10), 1159-1164 (2007).
25. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112(1), 26-34 (2006).
26. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J. Control. Release 125(3), 193-209 (2008).
27. Jiang WL, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 57(3), 391-410 (2005).
28. Zhang Z, Tongchusak S, Mizukami Y et al. Induction of anti-Tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 32(14), 3666-3678 (2011).
29. Ma W, Smith T, Bogin V et al. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: A promising strategy for tumor immunotherapy. J. Transl. Med. 9, 34 (2011).
30. Silva AL, Rosalia RA, Sazak A et al. Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: Low-burst release is crucial for efficient CD8(+) T cell activation. Eur. J. Pharm. Biopharm. 83(3), 338-345 (2013).
31. Marasini N, Skwarczynski M, Toth I. Oral delivery of nanoparticle-based vaccines. Expert Rev. Vaccin.(2014) (In Press).
32. Fievez V, Plapied L, Plaideau C et al. In vitro identification of targeting ligands of human M cells by phage display. Int. J. Pharm. 394(1-2), 35-42 (2010).
33. Clawson C, Huang C-T, Futalan D et al. Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomed. Nanotechnol. Biol. Med. 6(5), 651-661 (2010).
34. Tan S, Sasada T, Bershteyn A, Yang K, Ioji T, Zhang Z. Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-Tumor immunotherapy. Nanomedicine (London) 9(5), 635-647 (2014).
35. Fraser CC, H Altreuter D, Ilyinskii P et al. Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates. Vaccine 32(24), 2896-2903 (2014).
36. Taha MA, Singh SR, Dennis VA. Biodegradable PLGA85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide. Nanotechnology 23(32), (2012).
37. Li X, Min M, Du N et al. Chitin, chitosan, and glycated chitosan regulate immune responses: The novel adjuvants for cancer vaccine. Clin. Dev. Immunol. 2013, 387023 (2013).
38. Chua BY, Al Kobaisi M, Zeng W, Mainwaring D, Jackson DC. Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines. Mol. Pharm. 9(1), 81-90 (2012).
39. Shih IL, Van YT, Shen MH. Biomedical applications of chemically and microbiologically synthesized poly(glutamic acid) and poly(lysine). Mini-Rev. Med. Chem. 4(2), 179-188 (2004).
40. Yamaguchi S, Tatsumi T, Takehara T et al. EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-Tumor effect against mouse liver tumor. Cancer Immunol. Immunother. 59(5), 759-767 (2010).
41. Akagi T, Baba M, Akashi M. Preparation of nanoparticles by the self-organization of polymers consisting of hydrophobic and hydrophilic segments: Potential applications. Polymer 48(23), 6729-6747 (2007).
42. Skwarczynski M, Zaman M, Urbani CN et al. Polyacrylate dendrimer nanoparticles: A self-Adjuvanting vaccine delivery system. Angew. Chem. Int. Ed. Engl. 49(33), 5742-5745 (2010).
43. Zaman M, Skwarczynski M, Malcolm JM et al. Self-Adjuvanting polyacrylic nanoparticulate delivery system for group A Streptococcus (GAS) vaccine. Nanomed. Nanotechnol. Biol. Med. 7(2), 168-173 (2011).
44. Fuaad A, Jia ZF, Zaman M et al. Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine. Nanomedicine 9(1), 35-43 (2014).
45. Liu T-Y, Hussein WM, Jia Z et al. Self-Adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. Biomacromolecules 14(8), 2798-2806 (2013).
46. Nuhn L, Hartmann S, Palitzsch B et al. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines. Angew. Chem. Int. Ed. Engl. 52(40), 10652-10656 (2013).
47. Brandt ER, Sriprakash KS, Hobb RI et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian aboriginal population. Nat. Med. 6(4), 455-459 (2000).
48. Ghaffar KA, Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposomes as nanovaccine delivery systems. Curr. Top. Med. Chem. 14(9), 1194-1208 (2014).
49. Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposome-based delivery system for vaccine candidates: Constructing an effective formulation. Nanomedicine 7(12), 1877-1893 (2012).
50. Jalali SA, Sankian M, Tavakkol-Afshari J, Jaafari MR. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomedicine 8(5), 692-701 (2012).
51. Tai W, Roberts L, Seryshev A et al. Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic. Mucosal Immunol. 4(2), 197-207 (2011).
52. Skwarczynski M, Parhiz BH, Soltani F et al. Lipid peptide core nanoparticles as multivalent vaccine candidates against Streptococcus pyogenes. Aust. J. Chem. 65, 35-39 (2012).
53. Zhong W, Skwarczynski M, Toth I. Lipid core peptide system for gene, drug, and vaccine delivery. Aust. J. Chem. 62(9), 956-967 (2009).
54. Skwarczynski M, Zaman M, Toth I. Lipo-peptides/ saccharides in peptide vaccine delivery. In: Handbook of the Biologically Active Peptides (2nd Edition). Kastin A (Ed.). Elsevier, Inc., MA, USA, 571-579 (2013).
55. Skwarczynski M, Fuaad AaHA, Rustanti L et al. Group A streptococcal vaccine candidates based on the conserved conformational epitope from M protein. Drug Delivery Lett. 1, 2-8 (2011).
56. Skwarczynski M, Kamaruzaman KA, Srinivasan S et al. M-Protein-derived conformational peptide epitope vaccine candidate against group A Streptococcus. Curr. Drug Deliv. 10(1), 39-45 (2013).
57. Zaman M, Abdel-Aal A-BM, Fujita Y et al. Structure-Activity relationship for the development of a self-Adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes. J. Med. Chem. 55(19), 8515-8523 (2012).
58. Boato F, Thomas RM, Ghasparian A, Freund-Renard A, Moehle K, Robinson JA. Synthetic virus-like particles from self-Assembling coiled-coil lipopeptides and their use in antigen display to the immune system. Angew. Chem. Int. Ed. 46(47), 9015-9018 (2007).
59. Riedel T, Ghasparian A, Moehle K, Rusert P, Trkola A, Robinson JA. Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design. ChemBioChem 12(18), 2829-2836 (2011).
60. Sharma R, Ghasparian A, Robinson JA, McCullough KC. Synthetic virus-like particles target dendritic cell lipid rafts for rapid endocytosis primarily but not exclusively by macropinocytosis. PLoS ONE 7(8), e43248 (2012).
61. Roy A, Franco OL, Mandal SM. Biomedical exploitation of self assembled peptide based nanostructures. Cur. Protein Pept. Sci. 14(7), 580-587 (2013).
62. Chesson CB, Huelsmann EJ, Lacek AT et al. Antigenic peptide nanofibers elicit adjuvant-free CD8(+) T cell responses. Vaccine 32(10), 1174-1180 (2014).
63. Chen JJ, Pompano RR, Santiago FW et al. The use of self-Adjuvanting nanofiber vaccines to elicit high-Affinity B cell responses to peptide antigens without inflammation. Biomaterials 34(34), 8776-8785 (2013).
64. Rudra JS, Mishra S, Chong AS et al. Self-Assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials 33(27), 6476-6484 (2012).
65. Rudra JS, Tian YF, Jung JP, Collier JH. A self-Assembling peptide acting as an immune adjuvant. Proc. Natl Acad. Sci. USA 107(2), 622-627 (2010).
66. Skwarczynski M, Kowapradit J, Ziora ZM, Toth I. pH-Triggered peptide self-Assembly into fibrils: A potential peptide-based subunit vaccine delivery platform. Biochemical Compounds. http://dx.doi.org/10.7243/2052-9341-1-2
67. Kaba SA, Brando C, Guo Q et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol. 183(11), 7268-7277 (2009).
68. Yang Y, Neef T, Mittelholzer C et al. The biodistribution of self-Assembling protein nanoparticles shows they are promising vaccine platforms. J. Nanobiotechnol. 11, 36 (2013).
69. El Bissati K, Zhou Y, Dasgupta D et al. Effectiveness of a novel immunogenic nanoparticle platform for toxoplasma peptide vaccine in HLA transgenic mice. Vaccine 32(26), 3243-3248 (2014).
70. Ojea-Jimenez I, Comenge J, Garcia-Fernandez L, Megson ZA, Casals E, Puntes VF. Engineered inorganic nanoparticles for drug delivery applications. Curr. Drug Metab. 14(5), 518-530 (2013).
71. Lindblad EB. Aluminium adjuvants: In retrospect and prospect. Vaccine 22(27-28), 3658-3668 (2004).
72. Frey A, Mantis N, Kozlowski PA et al. Immunization of mice with peptomers covalently coupled to aluminum oxide nanoparticles. Vaccine 17(23-24), 3007-3019 (1999).
73. Frey A, Neutra MR, Robey FA. Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal vaccine candidates: Synthesis and characterization of a conjugate derived from the C4 domain of HIV-1(MN) gp120. Bioconjug. Chem. 8(3), 424-433 (1997).
74. Chen Y-S, Hung Y-C, Lin W-H, Huang GS. Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-And-mouth disease virus peptide. Nanotechnology 21(19), 195101 (2010).
75. Chiu D, Zhou W, Kitayaporn S et al. Biomineralization and size control of stable calcium phosphate core-protein shell nanoparticles: Potential for vaccine applications. Bioconjugate Chem. 23(3), 610-617 (2012).
76. Powell TJ, Palath N, Derome ME, Tang J, Jacobs A, Boyd JG Synthetic Nanoparticle Vaccines Produced by Layer-by-layer Assembly of Artificial Biofilms Induce Potent Protective T-cell and Antibody Responses in Vivo Vaccine 29(3), 558-569 (2011).
77. Mehra NK, Mishra V, Jain NK. A review of ligand tethered surface engineered carbon nanotubes. Biomaterials 35(4), 1267-1283 (2014).
78. Foldvari M, Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomed. Nanotechnol. Biol. Med. 4(3), 183-200 (2008).
79. Fadel TR, Fahmy TM. Immunotherapy applications of carbon nanotubes: From design to safe applications. Trends Biotechnol. 32(4), 198-209 (2014).
80. Gottardi R, Douradinha B. Carbon nanotubes as a novel tool for vaccination against infectious diseases and cancer. J. Nanobiotechnol. 11, 30 (2013).
81. Yandara N, Pastorin G, Prato M, Bianco A, Patarroyo ME, Lozano JM. Immunological profile of a Plasmodium vivax AMA-1 N-Terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model. Vaccine 26(46), 5864-5873 (2008).
82. Pantarotto D, Partidos CD, Graff R et al. Synthesis, structural characterization, and immunological properties of carbon nanotubes functionalized with peptides. J. Am. Chem. Soc. 125(20), 6160-6164 (2003).
83. Villa CH, Dao T, Ahearn I et al. Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-Associated antigens. ACS Nano 5(7), 5300-5311 (2011).